CADTH Canadian Drug Expert Committee recommendation: Nintedanib (Ofev -- Boehringer Ingelheim Canada Inc.) indication: chronic fibrosing interstitial lung diseases
The CADTH Canadian Drug Expert Committee recommends that nintedanib be reimbursed for the treatment of chronic fibrosing interstitial lung diseases with a progressive phenotype only if certain conditions are met
Corporate Author: | |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2021, February 26, 2021
|
Edition: | Version 1.0 |
Series: | CADTH common drug review
|
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The CADTH Canadian Drug Expert Committee recommends that nintedanib be reimbursed for the treatment of chronic fibrosing interstitial lung diseases with a progressive phenotype only if certain conditions are met |
---|---|
Physical Description: | 1 PDF file (8 pages) |